Marguerite Murray

Marguerite Murray

Auto-generated profile, based on publicly available information

Marguerite Murray

Department of Biomedical Engineering, College of Science and Engineering, University of Minnesota, 7-105 Nils Hasselmo Hall, 312 Church St SE, Minneapolis, Minnesota 55455, United States

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2025 in ACS Chemical Neuroscience
Verified
Journal Article
Open access
NKNoah Nathan Kochen
Noah Nathan Kochen
MMMarguerite Murray
Marguerite Murray
SZSophia Zafari
Sophia Zafari
NVNagamani Vunnam
Nagamani Vunnam
ELElly E. Liao
Elly E. Liao
JSJonathan N. Sachs
Jonathan N. Sachs
Pathological aggregates of TDP-43 are implicated in Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. While therapeutic efforts have traditionally focused on mitigating end-stage TDP-43 aggregation, recent evidence highlights an upstream and potentially targetable event: the loss of functional nuclear TDP-43 multimers due to disrupted N-terminal domain (NTD) interactions. To address this, we developed fluorescence lifetime (FLT)-based FRET biosensors to monitor TDP-43 multimerization in living cells that couple a full-length TDP-43 FLT-FRET biosensor screen with an NTD-deletion counter screen, forming the foundation of a novel high-throughput screening (HTS) platform. Screening the 2682 compound FDA-approved Selleck library, we identified the small molecule ketoconazole, which stabilizes functional nuclear TDP-43 multimers in an NTD-dependent manner with low micromolar potency. Ketoconazole rescues TDP-43 mislocalization and aggregation, restores SREBP2 mRNA levels under TDP-43 overexpression, improves neuronal health, and partially restores motor function in a TDP-43 C. elegans model. These findings establish both the biosensors and the HTS platform as innovative tools for TDP-43 drug discovery and support an exciting translational approach for targeting TDP-43 proteinopathies.

6 February 2026 in ACS Sensors
Verified
Journal Article
Closed access
ABAnthony R Braun
Anthony R Braun
ELElly E. Liao
Elly E. Liao
NVNagamani Vunnam
Nagamani Vunnam
SZSophia Zafari
Sophia Zafari
NKNoah Nathan Kochen
Noah Nathan Kochen
JSJonathan N. Sachs
Jonathan N. Sachs

12 May 2025 in Research Square
Verified
Preprint
Open access
PDF file
ABAnthony R Braun
Anthony R Braun
ELElly Liao
Elly Liao
NVNagamani Vunnam
Nagamani Vunnam
MMMarguerite Murray
Marguerite Murray
JSJonathan Sachs
Jonathan Sachs
Simultaneously monitoring multiple protein-protein interactions in live cells remains a key challenge in biology and drug discovery. While multiplexed FRET enables parallel molecular readouts, existing approaches are often constrained by spectral overlap, complex instrumentation, or incompatibility with live-cell models. To overcome these limitations and increase accessibility to the broader biological community, we present Multiplexed Dark FRET (MDF), a genetically encoded platform that uses spectrally distinct donors (mNeonGreen, mScarlet-I3) paired with non-emissive acceptors (ShadowY, ShadowR). Using fluorescence lifetime detection, we demonstrate MDF’s versatility through three biologically and translationally relevant examples: (1) cell-type specific biosensing in organoids, as exemplified in 3D neuro–glial spheroids; (2) target specificity for drug discovery, through discrimination of TNFR1 versus TNFR2 receptor conformations; and (3) protein misfolding, as exemplified through simultaneous monitoring of alpha-synuclein oligomerization and misfolding. MDF provides a scalable framework for real-time, live-cell biosensing across high-throughput, target-specific, and tissue-level applications in complex biological systems.